MACCARIO, Mauro
 Distribuzione geografica
Continente #
NA - Nord America 7.286
EU - Europa 5.276
AS - Asia 2.843
SA - Sud America 160
OC - Oceania 84
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.702
Nazione #
US - Stati Uniti d'America 7.088
CN - Cina 1.739
IT - Italia 1.006
SE - Svezia 760
IE - Irlanda 608
DE - Germania 588
UA - Ucraina 535
FR - Francia 409
GB - Regno Unito 371
FI - Finlandia 323
KR - Corea 319
CA - Canada 170
JP - Giappone 147
PL - Polonia 147
AT - Austria 122
VN - Vietnam 121
BR - Brasile 104
TR - Turchia 88
IN - India 84
ES - Italia 80
AU - Australia 79
GR - Grecia 60
HK - Hong Kong 60
NL - Olanda 51
TW - Taiwan 49
RU - Federazione Russa 39
BE - Belgio 38
SG - Singapore 30
PH - Filippine 27
PT - Portogallo 25
MY - Malesia 24
RO - Romania 22
IL - Israele 21
CH - Svizzera 20
JO - Giordania 20
MX - Messico 20
MU - Mauritius 19
ID - Indonesia 18
UZ - Uzbekistan 18
DK - Danimarca 16
AR - Argentina 15
NO - Norvegia 14
BG - Bulgaria 10
CO - Colombia 10
IR - Iran 9
TH - Thailandia 9
CL - Cile 8
PE - Perù 8
QA - Qatar 8
SN - Senegal 8
CZ - Repubblica Ceca 7
HU - Ungheria 7
PK - Pakistan 7
CY - Cipro 6
EC - Ecuador 6
ZA - Sudafrica 6
AF - Afghanistan, Repubblica islamica di 5
NZ - Nuova Zelanda 5
PY - Paraguay 5
BD - Bangladesh 4
EU - Europa 4
GT - Guatemala 4
KW - Kuwait 4
LB - Libano 4
NG - Nigeria 4
AE - Emirati Arabi Uniti 3
BA - Bosnia-Erzegovina 3
DZ - Algeria 3
EG - Egitto 3
IQ - Iraq 3
KZ - Kazakistan 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
CR - Costa Rica 2
EE - Estonia 2
ET - Etiopia 2
LK - Sri Lanka 2
PR - Porto Rico 2
SA - Arabia Saudita 2
SI - Slovenia 2
UY - Uruguay 2
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
GH - Ghana 1
KE - Kenya 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
MW - Malawi 1
PS - Palestinian Territory 1
RS - Serbia 1
UG - Uganda 1
VE - Venezuela 1
Totale 15.702
Città #
Beijing 1.368
Chandler 1.033
Dublin 593
Houston 557
Ashburn 307
Fairfield 288
Jacksonville 274
Ann Arbor 253
Medford 221
Wilmington 203
Dearborn 199
Nyköping 199
Woodbridge 184
Princeton 181
Villeurbanne 180
Redwood City 179
Milan 168
Torino 140
Vienna 114
Warsaw 113
Seattle 103
Cambridge 96
Boardman 78
Boston 73
Dong Ket 71
Verona 68
Pisa 62
Toronto 61
Turin 61
Lachine 43
Tokyo 39
Shanghai 38
Norwalk 32
Brussels 31
Guangzhou 31
Pune 30
Taipei 30
Munich 29
Fremont 28
Falls Church 27
Nanjing 26
Washington 26
Hangzhou 25
New York 25
Ankara 24
London 24
Rome 24
Hefei 23
Mountain View 23
São Paulo 22
Ottawa 21
Chengdu 19
Padova 18
Paris 17
Seoul 17
Central District 16
Cupertino 16
Delhi 15
Detroit 15
Istanbul 15
Kuala Lumpur 15
San Diego 15
Helsinki 14
Singapore 14
Absecon 13
Duncan 13
Hebei 13
San Mateo 13
Central 12
Düsseldorf 12
Moscow 12
Berlin 11
Kunming 11
Menlo Park 11
Philadelphia 11
Piemonte 11
Portland 11
Wuhan 11
Barcelona 10
Buenos Aires 10
Chicago 10
Melbourne 10
Redmond 10
Silver Spring 10
Tappahannock 10
Alcalá De Henares 9
Athens 9
Napoli 9
Polska 9
Changsha 8
Figtree 8
Hong Kong 8
Jakarta 8
Nanchang 8
Phoenix 8
Pittsburgh 8
Sofia 8
Zhengzhou 8
Birmingham 7
Brisbane 7
Totale 8.611
Nome #
Is the timing of caloric intake associated with variation in diet-induced thermogenesis and in the metabolic pattern? A randomized cross-over study 2.344
Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes 415
CUSHING'S SYNDROME IS ASSOCIATED WITH SLEEP ALTERATIONS DETECTED BY WRIST ACTIGRAPHY 326
Italian Association of Clinical Endocrinologists (AME) & Italian Association of Clinical Diabetologists (AMD) Position Statement : Diabetes mellitus and thyroid disorders: recommendations for clinical practice. 316
Somatic ATP1A1, ATP2B3, and KCNJ5 Mutations in Aldosterone-Producing Adenomas 299
Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. 286
Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. 266
Aldosterone suppression on contralateral adrenal during adrenal vein sampling does not predict blood pressure response after adrenalectomy. 261
Urinary cortisol and psychopathology in obese binge eating subjects. 233
Enhanced oxidative stress and platelet activation in patients with Cushing's syndrome. 215
Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults. 188
Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion. 183
HLA DRB1*0415: a new possible genetic susceptibility factor for Hirata's disease 174
Short-term fasting abolishes the sex-related difference in GH and leptin secretion in humans. 167
Mezzo di contrasto iodato e funzionalità tiroidea: una relazione da non sottovalutare. 159
Effects of meal timing on changes in circulating epinephrine, norepinephrine, and acylated ghrelin concentrations: A pilot study 144
Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa. 130
PERCORSO DIAGNOSTICOTERAPEUTICO ASSISTENZIALE DELLE MALATTIE TIROIDEE 128
Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. 123
Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. 123
Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. 117
Interactions of galanin and arginine on growth hormone, prolactin, and insulin secretion in man. 116
Diagnosis of GH deficiency in adults. 113
Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes 11 Medical and Health Sciences 1103 Clinical Sciences 112
Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus. 103
68 Ga-DOTA-TOC PET/CT of von Hippel-Lindau Disease 103
Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus. 102
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 102
Pirenzepine decreases basal and stimulated GH secretion in patients with type 2 (non-insulin-dependent) diabetes mellitus. 102
Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity. 101
Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. 101
Management of renal cancer in a contemporary series of patients affected by Von Hippel-Lindau disease. 101
Differential expressed proteins in urine samples from Von Hippel-Lindau disease and renal cell carcinoma patients versus healthy people. 99
The GH/IGF-I axis in obesity: influence of neuro-endocrine and metabolic factors. 97
[Neuroregulation of GH secretion in aging] 97
Comparison of Monotard and Ultratard insulin at bedtime in a model of optimized insulin therapy in Italy. 96
Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease. 94
Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children. 93
Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity? 92
HYPERCORTISOLISM DUE TO CUSHING’S DISEASE IS ASSOCIATED TO DERANGED GHRELIN SECRETION AND ACTION 92
Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term 91
Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. 89
Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. 86
Effects of direct and indirect acetylcholine receptor agonists on growth hormone secretion in humans. 85
Acylated ghrelin as provocative test for the diagnosis of ACTH deficiency in patients with hypothalamus–pituitary disease 82
Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. 82
Ageing, growth hormone and physical performance. 82
Pathophysiological doses of glucagon cause a transient increase of the hepatic vein potassium concentration in man. 81
Interaction of free fatty acids and arginine on growth hormone secretion in man. 81
Concomitant impairment of GH secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome 80
Pituitary-gonadal function in males with Down’s syndrome. 80
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 79
Interaction of salbutamol with pyridostigmine and arginine on both basal and GHRH-stimulated GH secretion in humans. 79
Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients 79
Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy 79
Biologic activities of growth hormone secretagogues in humans. 78
Alprazolam, a benzodiazepine, blunts but does not abolish the ACTH and cortisol response to hexarelin, a GHRP, in obese patients. 78
DIFFERENT ENDOCRINE-METABOLIC ABNORMALITIES BETWEEN “PURE” 45,XO TURNER’S SYNDROME AND MOSAICS 78
SENSITIVITY AND SPECIFICITY OF DIFFERENT PROVOCATIVE TESTS ASSESSING THE FUNCTION OF HYPOTHALAMO-PITUITARY-ADRENAL (HPA) AXIS IN PATIENTS SUSPECTED FOR SECONDARY HYPOADRENALISM 78
ADRENAL SENSITIVITY TO ACTH1-24 AS FUNCTION OF AGE, BODY WEIGHT AND PITUITARY FUNCTION 78
Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. 78
The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism 78
Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans. 77
Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency. 77
Radiofrequency ablation for thyroid nodules: which indications? The first Italian opinion statement 76
Assessment of GH/IGF-I axis in obesity by evaluation of IGF-I levels and the GH response to GHRH+arginine test. 75
Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients 75
ADRENAL SENSITIVITY TO ACTH1-24 AS FUNCTION OF AGE, BODY WEIGHT AND PITUITARY FUNCTION 75
Age-related endocrine and metabolic changes in simple obesity. 75
Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas 74
A multicenter epidemiological study on second malignancy in non-syndromic pheochromocytoma/paraganglioma patients in Italy 74
ADULT PATIENTS WITH DOWN’S SYNDROME SHOW ENHANCED BASAL TSH LEVELS BUT NORMAL TSH RESPONSE TO TRH 72
[Growth hormone and lipids] 71
Association of Urine Metanephrine Levels with Cardiometabolic Risk: An Observational Retrospective Study 71
Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus. 70
Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes. 69
Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study 69
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients 68
Comparisons among old and new provocative tests of GH secretion in 178 normal adults. 66
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index 65
Incidenza di alterazioni tiroidee dopo coronarografia con mezzo di contrasto iodato. 65
The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension. 64
Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. 64
L-Arginine 64
Low dose orally administered arginine is able to enhance both basLow dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children. 64
Treating with liraglutide an obese patient with type 2 diabetes mellitus and hereditary hemochromatosis 63
Use of the Diabetes Risk Score for Opportunistic Screening of Undiagnosed Diabetes and Impaired Glucose Tolerance: The IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study 63
Diagnostica neuroendocrina del paziente obeso (alterazioni neuroendocrine nel paziente obeso) 62
METABOLIC AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CUSHING’S SYNDROME OF DIFFERENT AETIOLOGY DURING ACTIVE DISEASE AND 1 YEAR AFTER REMISSION 62
Predictor Analysis in Radiofrequency Ablation of Benign Thyroid Nodules: A Single Center Experience 61
ENDOCRINE DISORDERS 60
From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma 59
Control and function of the GH-IGF-I axis in obesity. 59
Obstructive sleep apnea syndrome impairs insulin sensitivity independently of anthropometric variables 59
Obese patients with obstructive sleep apnoea syndrome show a peculiar alteration of the corticotroph but not of the tyhrotroph and lactotroph function 59
Ghrelin and other gastrointestinal peptides involved in the control of food intake 59
Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. 58
L-Arginine 58
Hyperthyroidism in patients with ischaemic heart disease after iodine load induced by coronary angiography: Long-term follow-up and influence of baseline thyroid functional status 58
Primary pigmented micronodular disease of the adrenals. 57
Totale 12.811
Categoria #
all - tutte 41.085
article - articoli 0
book - libri 0
conference - conferenze 3.019
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.104


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019533 0 0 0 0 0 0 0 0 0 144 266 123
2019/20202.455 107 89 183 219 251 533 239 161 238 177 164 94
2020/20211.961 146 117 177 100 242 125 176 102 222 192 129 233
2021/20221.923 70 87 101 106 116 92 142 119 99 224 327 440
2022/20233.091 338 217 67 347 312 741 229 188 328 74 148 102
2023/20241.215 196 241 93 105 150 200 58 104 15 53 0 0
Totale 16.262